Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers – Reports executive leadership changes and/or officer compensation arrangements as of January 9, 2026 Item 3.02: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year – Documents amendments to the company's bylaws or…

Our analysis rates this filing NEUTRAL. Henry Schein's CEO transition presents a balanced risk-reward profile typical of large-cap leadership changes. The three identified risks (severity 3-5) are material but not existential: CEO transitions inherently carry execution risk, but this one is planned…

Concern level: ELEVATED (5.2/10). Key factors: CEO transition with external hire lacking healthcare distribution experience - Frederick Lowery from Thermo Fisher brings life sciences background but limited exposure to medical/dental distribution core business; Significant CEO compensation increase (~$15.7M first-year value) may face shareholder scrutiny and impacts earnings per share; Governance…

Notable risk changes: CEO succession event: Stanley Bergman (long-tenured incumbent) transitioning to Chairman; Frederick Lowery (external hire from Thermo Fisher) appointed as new CEO effective March 2, 2026; Significant increase in CEO compensation package: ~$15.7M total first-year value including $10M equity grant and $2.5M sign-on award, substantially higher than prior CEO arrangements; Corporate governance…

The model predicts HSIC will underperform the S&P 500 by about 0.0% over 30 days (model confidence 65%). This is model analysis for research, not investment advice.